Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Trastuzumab deruxtecan (T-DXd) has shown promising clinical advancements for patients with HER2+ gastric cancer, according to the DESTINY-Gastric01 trial. Engaging explorations into HER2 biomarkers and resistance mechanisms highlight correlations that could shape future therapies. This vital research was led by an exceptional team of authors.... show more

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

N. Harbeck, E. Ciruelos, et al.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

S. Peters, S. M. Gadgeel, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny